2000/77/EC: Commission Decision of 17 December 1999 for the purchase by the Community of foot-and-mouth disease antigens and for the formulation, production, bottling and distribution of vaccines against foot-and-mouth disease (notified under document number C(1999) 4683)
4. 2. 2000 EN Official Journal of the European Communities L 30/35 COMMISSION DECISION of 17 December 1999 for the purchase by the Community of foot-and-mouth disease antigens and for the formulation, production, bottling and distribution of vaccines against foot-and-mouth disease (notified under document number C(1999) 4683) (2000/77/EC) THE COMMISSION OF THE EUROPEAN COMMUNITIES, Having regard to the Treaty establishing the European Community, Having regard to Council Decision 90/424/EEC of 26 June 1990 on expenditure in the veterinary field (1), as last amended by Regulation (EC) No 1258/1999 (2), and in particular Article 14 thereof, 1991 Having regard to Council Decision 91/666/EEC of 11 reserves December of foot-and-mouth disease vaccines (3), amended by Council Decision 1999/762/EC (4), and in particular Article 5 thereof, Community last as establishing Whereas: (5) The measures provided for in this Decision are in accordance with the opinion of the Standing Veterinary Committee, HAS ADOPTED THIS DECISION: Article 1 The Community shall purchase as soon as possible the 1. following strains of foot-and-mouth disease antigen: - A Iran 96: 1 000 000 doses, - A Iran 99: 1 000 000 doses, (1) In conformity with Decision 91/666/EEC, the purchase of antigens is a part of the Community action to establish Community reserves of foot-and-mouth disease vaccines. - A Malaysia 97: 500 000 doses, - SAT1: 500 000 doses, (2) By Commission Decision 93/590/EC of 5 November 1993 for the purchase by the Community of foot-and-mouth disease antigens within the framework of the Community foot-and-mouth disease action concerning reserves of vaccines (5), as last amended by Decision 95/471/EC (6), arrangements were made for purchase of A5, A22 and O1 foot-and-mouth disease antigen. - SAT2 (Southern Africa): 500 000 doses, - SAT2 (East Africa): 500 000 doses, - SAT3: 500 000 doses. (3) By Commission Decision 97/348/EC of 23 May 1997 for foot-and-mouth the purchase by the Community of the formulation, production, disease antigens and for bottling against vaccines and foot-and-mouth disease (7), arrangements were made for purchase of A22 Iraq, C1 and ASIA1 foot-and-mouth disease antigen. distribution of The Community for 2. formulation, production, bottling and distribution of vaccines against foot-and-mouth disease produced from antigens referred to in paragraph 1. arrangements shall make The maximum cost of 3. paragraphs 1 and 2 shall be up to EUR 2,5 million. the measures referred to in (4) Owing to the disease situation, additional antigens are required. The action referred to in paragraph 3 shall be organised 4. by the Commission before 31 December 1999. (1) OJ L 224, 18. 8. 1990, p. 19. (2) OJ L 160, 26. 6. 1999, p. 103. (3) OJ L 368, 31. 12. 1991, p. 21. (4) OJ L 301, 24. 11. 1999, p. 6. (5) OJ L 280, 13. 11. 1993, p. 33. (6) OJ L 269, 11. 11. 1995, p. 29. (7) OJ L 148, 6. 6. 1997, p. 27. Article 2 The measures mentioned in Article 1(3) shall be carried out by the Commission in cooperation with the supplier designated by call for tender. L 30/36 EN Official Journal of the European Communities 4. 2. 2000 Article 3 Article 4 To meet 1. Commission shall conclude contracts without delay. the objectives of Articles 1 and 2 the The Director-General of 2. for Health and Consumer Protection shall be authorised to sign the contracts on behalf of the European Commission. the Directorate-General This Decision is addressed to the Member States. Done at Brussels, 17 December 1999. For the Commission David BYRNE Member of the Commission